Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells.

Muniraj N, Siddharth S, Nagalingam A, Walker A, Woo J, Gyorffy B, Gabrielson E, Saxena NK, Sharma D.

Carcinogenesis. 2019 Jan 29. doi: 10.1093/carcin/bgz015. [Epub ahead of print]

PMID:
30698683
2.
3.

ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis.

Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, Woo J, Győrffy B, Gabrielson E, Saxena NK, Sharma D.

Autophagy. 2017 Aug 3;13(8):1386-1403. doi: 10.1080/15548627.2017.1332565. Epub 2017 Jul 11.

4.

Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.

Sengupta S, Nagalingam A, Muniraj N, Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S, Korangath P, Shriver M, Begum A, Merino VF, Huang CY, Arbiser JL, Matsui W, Győrffy B, Konstantopoulos K, Sukumar S, Marignani PA, Saxena NK, Sharma D.

Oncogene. 2017 Oct 12;36(41):5709-5721. doi: 10.1038/onc.2017.164. Epub 2017 Jun 5.

5.

Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis.

Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D.

Breast Cancer Res. 2017 Mar 28;19(1):39. doi: 10.1186/s13058-017-0829-2. No abstract available.

6.

Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes.

Xie B, Nagalingam A, Kuppusamy P, Muniraj N, Langford P, Győrffy B, Saxena NK, Sharma D.

Sci Rep. 2017 Jan 10;7:40070. doi: 10.1038/srep40070.

7.

Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis.

Avtanski DB, Nagalingam A, Tomaszewski JE, Risbood P, Difillippantonio MJ, Saxena NK, Malhotra SV, Sharma D.

Mol Oncol. 2016 Aug;10(7):1118-32. doi: 10.1016/j.molonc.2016.04.003. Epub 2016 May 20.

8.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

9.

Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.

Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Oncotarget. 2015 Oct 6;6(30):29947-62. doi: 10.18632/oncotarget.4937.

10.

Withaferin-A Reduces Acetaminophen-Induced Liver Injury in Mice.

Jadeja RN, Urrunaga NH, Dash S, Khurana S, Saxena NK.

Biochem Pharmacol. 2015 Sep 1;97(1):122-32. doi: 10.1016/j.bcp.2015.07.024. Epub 2015 Jul 23.

11.

Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner.

Avtanski DB, Nagalingam A, Kuppusamy P, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Oncotarget. 2015 Jun 30;6(18):16396-410.

12.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S.

Semin Cancer Biol. 2015 Dec;35 Suppl:S25-S54. doi: 10.1016/j.semcancer.2015.02.006. Epub 2015 Apr 17. Review.

13.

Adipocytokines and hepatic fibrosis.

Saxena NK, Anania FA.

Trends Endocrinol Metab. 2015 Mar;26(3):153-61. doi: 10.1016/j.tem.2015.01.002. Epub 2015 Feb 2. Review.

14.

Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis.

Kumar P, Smith T, Rahman K, Mells JE, Thorn NE, Saxena NK, Anania FA.

FASEB J. 2014 Dec;28(12):5172-83. doi: 10.1096/fj.14-253229. Epub 2014 Aug 25.

15.

Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer.

Nagalingam A, Kuppusamy P, Singh SV, Sharma D, Saxena NK.

Cancer Res. 2014 May 1;74(9):2617-29. doi: 10.1158/0008-5472.CAN-13-2081. Epub 2014 Apr 14.

16.

Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Mol Oncol. 2014 May;8(3):565-80. doi: 10.1016/j.molonc.2014.01.004. Epub 2014 Jan 15.

17.

Multifaceted leptin network: the molecular connection between obesity and breast cancer.

Saxena NK, Sharma D.

J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):309-20. doi: 10.1007/s10911-013-9308-2. Epub 2013 Nov 10. Review.

18.

Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis.

Taliaferro-Smith L, Nagalingam A, Knight BB, Oberlick E, Saxena NK, Sharma D.

Neoplasia. 2013 Jan;15(1):23-38.

19.

Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.

Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD.

Cancer Prev Res (Phila). 2012 Apr;5(4):544-52. doi: 10.1158/1940-6207.CAPR-11-0228. Epub 2012 Mar 31.

20.
21.

Med1 plays a critical role in the development of tamoxifen resistance.

Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK, Sharma D.

Carcinogenesis. 2012 Apr;33(4):918-30. doi: 10.1093/carcin/bgs105. Epub 2012 Feb 16.

22.

Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways.

Yan D, Avtanski D, Saxena NK, Sharma D.

J Biol Chem. 2012 Mar 9;287(11):8598-612. doi: 10.1074/jbc.M111.322800. Epub 2012 Jan 23.

23.

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.

Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA.

Am J Physiol Gastrointest Liver Physiol. 2012 Jan 15;302(2):G225-35. doi: 10.1152/ajpgi.00274.2011. Epub 2011 Oct 28.

24.

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.

Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA.

PLoS One. 2011;6(9):e25269. doi: 10.1371/journal.pone.0025269. Epub 2011 Sep 21.

25.

Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis.

Handy JA, Fu PP, Kumar P, Mells JE, Sharma S, Saxena NK, Anania FA.

Biochem J. 2011 Dec 15;440(3):385-95. doi: 10.1042/BJ20102148.

26.

Chryseobacterium indologenes bacteraemia in a preterm baby.

Sudharani V; Asiya, Saxena NK.

Indian J Med Microbiol. 2011 Apr-Jun;29(2):196-8. doi: 10.4103/0255-0857.81783. No abstract available.

27.

Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells.

Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, Sharma D.

Endocr Relat Cancer. 2011 Jul 1;18(4):413-28. doi: 10.1530/ERC-11-0075. Print 2011 Aug.

28.

Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3.

Kim SH, Nagalingam A, Saxena NK, Singh SV, Sharma D.

Carcinogenesis. 2011 Mar;32(3):359-67. doi: 10.1093/carcin/bgq267. Epub 2010 Dec 16.

29.

Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis.

Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, Saxena NK.

Hepatology. 2010 Nov;52(5):1713-22. doi: 10.1002/hep.23892.

30.

Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.

Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, Tighiouart M, Sharma D, Anania FA.

Gastroenterology. 2010 Nov;139(5):1762-73, 1773.e1-5. doi: 10.1053/j.gastro.2010.07.001. Epub 2010 Jul 13.

31.

Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3).

Handy JA, Saxena NK, Fu P, Lin S, Mells JE, Gupta NA, Anania FA.

J Cell Biochem. 2010 Aug 1;110(5):1195-207. doi: 10.1002/jcb.22634. Erratum in: J Cell Biochem. 2011 Feb;112(2):734.

32.

Metastasis suppression by adiponectin: LKB1 rises up to the challenge.

Saxena NK, Sharma D.

Cell Adh Migr. 2010 Jul-Sep;4(3):358-62. Epub 2010 Jul 17.

33.

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.

Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA.

Hepatology. 2010 May;51(5):1584-92. doi: 10.1002/hep.23569.

34.

Unresolving pericarditis: suspect filariasis in the tropics.

Prasanthi K, Nagamani K, Saxena NK.

Indian J Med Microbiol. 2010 Jan-Mar;28(1):73-5. doi: 10.4103/0255-0857.58738.

35.
36.

LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells.

Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D.

Oncogene. 2009 Jul 23;28(29):2621-33. doi: 10.1038/onc.2009.129. Epub 2009 Jun 1.

37.

Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.

Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, Sharma D.

Cancer Res. 2008 Dec 1;68(23):9712-22. doi: 10.1158/0008-5472.CAN-08-1952.

38.

Molecular characterisation of Cryptosporidium: an emerging parasite.

Nagamani K, Pavuluri PR, Gyaneshwari M, Prasanthi K, Rao MI, Saxena NK.

Indian J Med Microbiol. 2007 Apr;25(2):133-6.

39.
40.
41.

WISP-2/CCN5 is involved as a novel signaling intermediate in phorbol ester-protein kinase Calpha-mediated breast tumor cell proliferation.

Sengupta K, Banerjee S, Dhar K, Saxena NK, Mehta S, Campbell DR, Banerjee SK.

Biochemistry. 2006 Sep 5;45(35):10698-709.

PMID:
16939222
42.
44.
45.

Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor.

Islam A, Banerjee S, Kambhampati S, Baranda J, Banerjee S, Weston AP, Saxena NK, Banerjee SK.

Front Biosci. 2006 Sep 1;11:2336-48. Review.

PMID:
16720317
46.

Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways.

Ray G, Dhar G, Van Veldhuizen PJ, Banerjee S, Saxena NK, Sengupta K, Banerjee SK.

Biochemistry. 2006 Mar 21;45(11):3703-13.

PMID:
16533053
47.

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.

Ding X, Saxena NK, Lin S, Gupta NA, Anania FA.

Hepatology. 2006 Jan;43(1):173-81. Erratum in: Hepatology. 2006 Aug;44(2):515. Gupta, Narita [corrected to Gupta, Nitika Arora].

48.

The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology.

Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA.

Am J Pathol. 2005 Jun;166(6):1655-69. Erratum in: Am J Pathol. 2008 Dec;173(6):1929. Xu, Amin [corrected to Xu, Aimin].

49.
50.

Supplemental Content

Loading ...
Support Center